الفهرس 
AbbreviationsOnly 14 pages are availabe for public view
 |  | from | 184 |  |  |
| | | from | 184 | | |
Abstract
Neuroinflammatory changes and cognitive dysfunction are increasingly recognized as complications of type 2 diabetes mellitus (T2DM). Moreover, research has uncovered a strong metabolic component in neurodegenerative disorders, including Alzheimer’s Disease, to the extent that the former is often referred to as type 3 diabetes. Despite a lack of disease-modifying therapeutic interventions for cognitive disorders, interest has surged in the potential neuroprotective effects of novel anti-diabetic drugs. This study investigates the impact of combining metformin with the new antidiabetic drugs, dipeptidyl peptidase-4 inhibitors (DPP-4i) or sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cognitive decline in T2DM patients.
Our prospective observational cohort study compared T2DM patients taking metformin with either DPP-4i or SGLT2i combination therapy to a group of patients on metformin monotherapy, in addition to a group of healthy non-diabetics to serve as a baseline reference.